智通财经7月7日电，日前，湖南省市际联盟(湘潭)创口敷料类医用耗材集中带量采购线上报价与信息公 开会在湘潭市医保局召开，标志着此次覆盖全省的高端创口敷料集采进入关键阶段。前期，采购文件制 定发布、企业产品申报、医疗机构需求量填报等环节已完成。作为集采流程核心环节，此次共有181家 企业报价。根据企业报价结果初步测算，各类产品价格平均降幅达70%，预计今年底前落地执行。中选 结果将直接影响未来两年湖南省相关医疗机构的创口敷料供应结构和采购成本。 (湖南日报) 湖南首次集采高端创口敷料 平均降价达70% ...

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly misleading investors about the company's business prospects during the period from February 16, 2023, to February 12, 2025 [1][2]. Allegations - The lawsuit claims that West Pharmaceutical failed to disclose significant ongoing destocking in its high-margin HVP portfolio, contrary to its assertions of strong customer demand [2]. - It is alleged that the SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2]. - The margin pressures faced by the company raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-standing customers [2]. - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2]. Disclosure of Truth - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to the loss of two major CGM customers transitioning to in-house manufacturing [3]. - West also indicated that its SmartDose devices would be margin dilutive in 2025 and mentioned that steps would be taken to improve the economics of the SmartDose [3]. - Following this announcement, West's stock price fell by $123.17 per share, a decline of approximately 38%, closing at $199.11 on February 13, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 7, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Becton, Dickinson and Company (NYSE: BDX) is identified as a leading provider of medical supplies with significant undervaluation and a high dividend yield of nearly 2.5%, the highest in over a decade [1] Company Overview - Becton, Dickinson operates in various sectors including life sciences, infusion, and diagnostics [1] - The company is noted for its excellent dividend safety, making it an attractive option for dividend growth investors [1] Investment Strategy - The focus is on identifying undervalued large-cap stocks with sustainable dividend growth and potential for capital appreciation [1] - There is also an interest in tech and small- or mid-cap stocks for their growth potential, regardless of dividend status [1] Performance Metrics - The dividend yield of BDX is highlighted as being the highest in over ten years, indicating strong performance in terms of returns to shareholders [1]

Analyst & Investor Day May 22, 2025 New York, New York 1 Welcome to Analyst & Investor Day Pravesh Khandelwal Vice President, Investor Relations 2 2 Forward-looking statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results ...

Core Insights - United-Guardian, Inc. reported a decline in both net sales and net income for the first quarter of 2025, with net sales at $2.48 million, down 24% from $3.25 million year-over-year, and net income falling 39% to $560,895 or 12 cents per share from $925,442 or 20 cents per share [2][6] Business Segment Performance - The cosmetic ingredients segment experienced a significant decline, with sales dropping 63% year-over-year to $698,998 from $1.88 million, primarily due to a 74% reduction in orders from its largest distributor, Ashland Specialty Ingredients [3] - Pharmaceutical sales rebounded, with net sales increasing 23% to $1.17 million from $950,323 in the previous year, driven by the normalization of Renacidin supply, which saw gross sales rise 38% year-over-year to $1.23 million [4] - Medical lubricant sales grew 43% year-over-year to $613,671, benefiting from increased demand in India and China, making it the strongest performing segment [5] Management Commentary - The company's president acknowledged the challenging start to the year, attributing revenue shortfalls to the cosmetic ingredient business but highlighted the strength in medical lubricants and pharmaceuticals as positive signs [6] - Concerns were raised regarding evolving trade policies and tariffs by the U.S. government, which could introduce uncertainty for product lines tied to China markets, although the company is monitoring these risks [7] Financial Metrics - Cost of sales decreased to $1.12 million from $1.56 million year-over-year, improving as a percentage of revenues to 45% from 48% [8] - Operating expenses rose 11% to $632,735 due to higher payroll and marketing costs, while research and development expenses also increased by 11% to $114,394 [8] - Investment income and gains on marketable securities fell to $97,037 from $139,569 a year earlier, attributed to lower interest income and reduced unrealized gains [9] Future Outlook - The company expressed confidence in its long-term strategy, particularly in product development and market expansion, with plans to begin manufacturing and sales of the Natrajel product in 2025 [10] - In February 2025, United-Guardian expanded its partnership with Azelis Group NV to include South Korea and broadened coverage in the U.K. and Ireland [11]

According to the complaint, during the class period, defendants failed to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) t ...

Financial Performance - United-Guardian, Inc. reported a decrease in first quarter sales from $3,254,944 in 2024 to $2,481,127 in 2025, representing a decline of approximately 23.7% [1][4] - Net income also decreased from $925,442 ($0.20 per share) in 2024 to $560,895 ($0.12 per share) in 2025, reflecting a decline of about 39.3% [1][5] Business Segment Performance - The medical lubricant and pharmaceutical segments showed positive performance, with sales increasing by 43% and 23% respectively in the first quarter of 2025 compared to the same period in 2024 [2] - Conversely, sales in the cosmetic ingredient segment decreased significantly by 63% in the first quarter of 2025, primarily due to reduced orders from Ashland Specialty Ingredients (ASI) [2] Operational Insights - The decrease in orders from ASI was attributed to excess inventory in China that needed to be worked off and the timing of product orders, although ASI confirmed no significant loss of business or customers [2] - The company expressed concerns regarding potential impacts from tariff announcements by the U.S. federal government on imports, indicating uncertainty in future operations and financial conditions [2]

2025 Outlook - The company projects revenue between $10.85 billion and $11.15 billion[7] - Gross margin is expected to be between 20.75% and 21.25%[7] - Interest expense is estimated to be between $138 million and $142 million[7] - Gross capital expenditures are projected to be between $250 million and $270 million[7] - Net capital expenditures are expected to be between $180 million and $205 million[7] - The adjusted effective tax rate is projected to be between 29.0% and 30.0%[7] - Diluted weighted average shares outstanding are expected to be approximately 80 million[7] - Adjusted EBITDA is projected to be between $560 million and $590 million[7] - Adjusted EPS is projected to be between $1.60 and $1.85[7] - The outlook assumes stable commodity prices and foreign currency rates as of December 31, 2024[7]

SAN DIEGO, May 7, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025. West is a medical supplies company that specializes in the development, manufacture, and distribution of elastomer-based supplies for the containment and administration of injectable drugs.For more information, submit a form, ...

标项一 标项名称:常规2包试剂及试剂辅助耗材 数量:不限 预算金额（元）: 9 0 0 0 0 0 0 单位： 批 简要规格描述或项目基本概况介绍、用途：详见采购文件 备注： 导读： 新疆维吾尔自治区传染病医院临床检验试剂及试剂辅助耗材采购项目，预算金额（元）：22550000。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 一、项目基本情况 项目编号：HCZB- 2 0 2 4 -ZB1 6 6 5（三次） 项目名称：新疆维吾尔自治区传染病医院临床检验试剂及试剂辅助耗材采购项目（三次） 采购方式：公开招标 预算金额（元）：2 2 5 5 0 0 0 0 最高限价（元）：/,/,/,/,/,/,/,/,/ 采购需求： 三、对本次采购提出询问，请按以下方式联系 1 .采购人信息 标项二 标项名称:常规免疫试剂及试剂辅助耗材 数量:不限 预算金额（元）: 4 5 0 0 0 0 0 单位： 批 简要规格描述或项目基本概况介绍、用途：详见采购文件 备注： 标项三 标项名称:分子3包试剂及试剂辅助耗材 数量:不限 预算金额（元）: 2 0 ...